Shijing Jia, MD
Pulmonary Disease · Ann Arbor, MINPI 1699066712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,012 of the $2,442 with a category attached, or 82.4%. Insmed, Inc. accounts for 90.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $2,086 and has fallen 83.6% since, to $342 in 2025.
Across 9 payments — averaging $271.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$2K
- Boehringer Ingelheim$146
- Verona Pharma, Inc.$55
- Chiesi USA, Inc.$31
Across 100 payments — averaging $4925.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$229K
- Verona Pharma, Inc.$130K
- Insmed, Inc.$85K
- Vertex$44K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$2,01282%
- Food & beverage$41617%
- Education$141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 4 | $2,209 |
| Boehringer Ingelheim | 2 | $146 |
| Verona Pharma, Inc. | 1 | $55 |
| Chiesi USA, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$124
How this compares
$2,442 in reported general payments places this provider in the 60th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 51 | $1,253,789 |
| Dupixent SyringeDupilumab | 22 | $79,488 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $14,253 |
| DuleraMometasone/Formoterol | 16 | $11,356 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $9,384 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,048 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,775 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $1,918 |
| Montelukast Sodium | 31 | $619 |
| Azithromycin | 22 | $321 |
| Omeprazole | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Ann Arbor
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Justin OldhamAnn Arbor$392K
- Kevin FlahertyAnn Arbor$328K
- Jose de CardenasAnn Arbor$115K
- Timothy BlackwellAnn Arbor$99K
- Philip ChoiAnn Arbor$54K
- Jeanette BrownAnn Arbor$38K
- Jeffrey CurtisAnn Arbor$37K
- Vibha LamaAnn Arbor$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.